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Abstract
Background: The benefit and timing of radiation therapy (RT) for patients undergoing a resection for
pancreatic adenocarcinoma remains unclear. This study identifies trends in the use of radiation over a
10-year period and factors associated with the use of pre-operative radiation, in particular.
Methods: The Surveillance, Epidemiology and End Results registry was used to identify patients aged
≥18 years with pancreatic adenocarcinoma who underwent a surgical resection between 2000 and
2010. Logistic regression was used to identify time trends and factors associated with the use of
pre-operative radiation.
Results: The overall use of radiation decreased with time among the 8474 patients who met the inclu-
sion criteria. However, the use of pre-operative radiation increased from 1.8% to 3.9% (P ≤ 0.05).
Factors significantly associated with receipt of pre-operative radiation were younger age, treatment in
more recent years and having an advanced T-stage tumour. The 5-year hazard of death was signifi-
cantly less for those who received pre-operative radiation versus surgery alone [hazard ratio (HR) 0.64,
95% confidence interval (CI) 0.55–0.74] and for those who received post-operative radiation versus
surgery alone (HR 0.69, 95% CI 0.65–0.73).
Discussion: The use of pre-operative radiation significantly increased during the study period.
However, the overall use of pre-operative radiation therapy remains low in spite of the potential benefits.
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Introduction
A number of studies have investigated the outcomes associated
with the use of post-operative adjuvant radiation therapy (RT)
for the treatment of pancreatic adenocarcinoma. The findings
of these studies have been largely inconsistent with some show-
ing a significant survival benefit with the use of chemoradia-
tion1–4 and others showing only a non-significant trend
towards an increase in survival.5–7 Complicating the picture
further, the European Study Group for Pancreatic Cancer Trial
1 (ESPAC-1) results suggested that post-operative chemoradia-
tion may even have a deleterious effect on survival.8 This
uncertainty regarding the benefits of post-operative chemoradi-
ation is reflected in the National Comprehensive Cancer
Network (NCCN) guidelines for post-operative adjuvant treat-
ment of pancreatic adenocarcinoma. After surgical resection,
the NCCN guidelines recommend enrolment in a clinical trial
of post-operative adjuvant therapy. If a clinical trial is not an
option, the NCCN guidelines recommend either chemoradia-
tion or chemotherapy alone as appropriate post-operative
adjuvant therapy.9
While the utility of post-operative radiation has been ques-
tioned, several single-institutional studies have reported the
outcomes and potential benefits of pre-operative chemoradia-
tion.10–14 Current NCCN guidelines recommend pre-operative
adjuvant therapy as an appropriate option for those with
borderline resectable disease and acknowledge that many
NCCN member institutions now prefer this approach for
This paper is an extension of the abstract that was presented in poster
format at the 48th Annual Pancreas Club Meeting, 2–3 May 2014,
Chicago, IL.
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borderline resectable patients. For patients with resectable dis-
ease, the panel recommends these patients enrol in a clinical
trial when pursuing pre-operative adjuvant therapy as opposed
to a surgery first approach.9 Currently, there are few data on
the frequency and trends of the use of pre-operative RT in the
United States or the predictive factors related to receipt of pre-
operative radiation therapy. This study evaluated trends in the
use of radiation in the pre- and post-operative setting, and
sought to identify demographic, patient and tumour predictors
that play a role in clinical decision-making. In addition, poten-
tial differences in survival were assessed between those patients
who received RT (either pre- or post-operative) versus those
who underwent surgery alone.
Methodology
Data
The Surveillance Epidemiology and End Results (SEER) pro-
gramme database was used to examine trends in the use of
pre- and post-operative RT for patients who underwent a
resection for the treatment of pancreatic adenocarcinoma
between 2000 and 2010. The SEER cancer registries provide
population-based cancer surveillance for 18 areas that represent
approximately 28% of the United States.15 SEER collects
patient demographic and tumour characteristics, including age
at diagnosis, race, primary tumour site, tumour laterality,
histology type, tumour stage, tumour grade, diagnostic confir-
mation, type of surgery, the use of radiation therapy, vital
status and the cause of death.
Patients
The study was limited to include only patients aged 18 years
and older diagnosed with microscopically confirmed pancreatic
adenocarcinoma and who had undergone a surgical resection
between 2000 and 2010. The analysis excluded patients with
non-adenocarcinoma pancreatic cancer, those with multiple
primary malignancies in a lifetime and those patients diagnosed
while in a nursing home, by autopsy, or on a death certificate.
Owing to the concern that registries with very few patients
receiving pre-operative RT could skew the analysis, registries
were excluded that reported fewer than 10 patients treated with
pre-operative RT over the 10-year analytic period. Twelve reg-
istries were included, and the six excluded registries comprised
Hawaii, New Mexico, Rural Georgia, San Francisco – Oakland,
San Jose – Monterey and the Alaska Native Tumor Registry.
Three treatment categories were created: surgery without
radiation, pre-operative radiation then surgery and surgery fol-
lowed by post-operative radiation. Surgical codes included a
partial pancreatectomy, NOS (SEER surgical code 30), local or
partial pancreatectomy and duodenectomy (without distal/
partial gastrectomy and with partial gastrectomy (Whipple);
35–37), a total pancreatectomy (40), a total pancreatectomy
with subtotal gastrectomy/duodenectomy (60), an extended
pancreatoduodenectomy (70) and a pancreatectomy, NOS (80).
Statistical analysis
Unadjusted treatment patterns were compared over the 10-year
study period using the Cochrane–Armitage test for trend.
Logistic regression was used to identify time trends, demo-
graphics and patient factors associated with the use of
pre-operative radiation therapy. All regression models included
the patients’ age, race, gender, year of diagnosis, tumour size,
T-stage, tumour grade, the number of lymph nodes examined,
lymph node status, treatment type and registry.
The Kaplan–Meier method and Cox’s proportional hazards
models were employed to determine the 5-year relative hazard
of death based on the treatment received. This model included
the patients’ age, race, gender, year of diagnosis, tumour size,
T-stage, tumour grade, number of lymph nodes examined,
lymph node status, treatment type and registry.
All statistical analysis was completed using SAS software,
version 9.3 (SAS Institute, Cary, NC, USA). This study was
exempt from review by the Human Subjects Committee of the
University of Minnesota’s Institutional Review Board because
it used a de-identified data source.
Results
Description of the population
From 2000 to 2010, 8474 patients were identified who under-
went a resection for pancreatic adenocarcinoma. Demographic,
pathological and treatment details are provided in Table 1.
Changes in treatment patterns over time
Overall, the use of RT for pancreatic adenocarcinoma signifi-
cantly decreased in the United States from 2000 to 2010
(45.9% to 32.6%, P ≤ 0.05). However, the use of pre-operative
RT modestly but significantly increased from 1.8% to 3.9%
(P ≤ 0.05). The use of surgery without radiation increased sig-
nificantly (P ≤ 0.05) from 54.1% (2000) to 67.4% (2010). At
the same time, the use of post-operative radiation significantly
decreased over time from 44.1% in 2000 to 28.7% in 2010
(P ≤ 0.05). Thus, the overall decrease in the use of RT is lar-
gely due to a decrease in the use of post-operative RT (Fig. 1).
Factors associated with pre-operative RT
Younger patient age and diagnosis and treatment in more recent
years were significantly associated with receipt of pre-operative
radiation (Table 2). Significant geographical differences in the
use of pre-operative radiation were observed but without
obvious broad geographical patterns. Tumour factors that were
significantly associated with an increase in pre-operative RT were
missing or unknown tumour grade and advanced T stage
(Table 2). Finally, there was a significant association between
receiving pre-operative RT and positive lymph node status at the
time of surgery (Table 2) suggesting that patients with higher
stage cancers identified clinically are more likely to get pre-
operative therapy. The number of lymph nodes evaluated was
not significantly associated with the use of pre-operative radiation.
HPB 2015, 17, 542–550 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 543
Table 1 Patient characteristics by treatment group
No RT (N = 5039)
N (%)
Pre-operative
RT (N = 299)
N (%)
Post-operative
RT (N = 3136)
N (%)
Year
2000–2004 1751 (34.7) 91 (30.4) 1364 (43.5)
2005–2010 3288 (65.3) 208 (79.6) 1772 (56.5)
Age
18–39 112 (2.2) 2 (0.6) 48 (1.5)
40–64 1939 (38.5) 179 (59.9) 1672 (53.3)
65+ 2988 (59.3) 118 (39.5) 1416 (45.2)
Gender
Male 2418 (48.0) 156 (52.2) 1606 (51.2)
Female 2621 (52.0) 143 (47.8) 1530 (48.8)
Race
Non-Hispanic white 4214 (83.6) 249 (83.3) 2680 (85.5)
Black 549 (10.9) 38 (12.7) 342 (10.9)
Other or unknown 276 (5.5) 12 (4.0) 114 (3.6)
Tumour size
<2 cm 604 (12.0) 21 (7.0) 298 (9.5)
≥2 cm 4210 (83.5) 259 (86.6) 2701 (86.1)
Missing 225 (4.5) 19 (6.4) 137 (4.4)
Tumour grade
1 or 2 2860 (56.8) 141 (47.2) 1834 (58.5)
3 1594 (31.6) 81 (27.1) 1039 (33.1)
4 66 (1.3) 3 (1.0) 36 (1.1)
Missing/unknown 519 (10.3) 74 (24.7) 227 (7.2)
T-stage
1 and 2 1440 (28.6) 52 (17.4) 653 (20.8)
3 3411 (67.7) 188 (62.9) 2314 (73.8)
4 188 (3.7) 59 (19.7) 169 (5.4)
Surgery type
Whipple 3525 (70.0) 225 (75.3) 2325 (74.1)
Total pancreatectomy 589 (11.7) 39 (13.0) 327 (10.4)
Other 925 (18.4) 35 (11.7) 484 (15.4)
Node positive
No 2295 (45.5) 197 (65.9) 1081 (34.5)
Yes 2744 (54.5) 102 (34.1) 2055 (65.5)
Nodes examined
0 236 (4.7) 26 (8.7) 94 (3.0)
1–9 1930 (38.3) 120 (40.1) 1105 (35.2)
10–14 1103 (21.9) 78 (26.1) 764 (24.4)
15+ 1673 (33.2) 68 (22.7) 1109 (35.4)
Unknown 97 (1.9) 7 (2.3) 64 (2.0)
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Survival analysis based on the type of treatment
In our unadjusted survival analysis models, the median survival
for those who received pre-operative radiation was 23 months
compared with 16 months for those who received no RT
(P ≤ 0.05). There was also a significantly improved median
survival for those who received post-operative radiation ther-
apy compared with those who received no RT (20 versus
16 months, P ≤ 0.05) (Fig. 2). However, at 5 years the survival
curves become indistinguishable.
On multivariate analysis, the use of either pre- or post-oper-
ative RT was associated with a significantly lower hazard of
death compared with no RT [pre-operative RT hazard ratio
(HR) 0.64, 95% confidence interval (CI) 0.55–0.74; postopera-
tive RT HR 0.69, 95% CI 0.65–0.73] (Table 3). A more recent
year of diagnosis, female gender, and non-Hispanic white race
were all associated with a decreased hazard of death (all P ≤
0.05). Patients aged 40–64 years had a significantly lower
hazard of death compared with those aged 18–39 years (HR
0.41, 95% CI 0.32–0.53). Patients 65 years of age or greater
also had a significantly lower hazard of death compared with
those aged 18–39 years (HR 0.81, 95% CI 0.77–0.85). There
was also significant geographic variation with regards to
survival; however, no clear geographic trends emerged
(Table 3). Tumour factors including larger tumour size, higher
T-stage, higher tumour grade and lymph node positivity were
all associated with an increased hazard of death (all P ≤ 0.05).
Discussion
The data regarding the survival benefit of radiation therapy,
when used in combination with chemotherapy, are inconsis-
tent. Recommendations for the routine use of post-operative
chemoradiation for the adjuvant treatment of pancreatic
adenocarcinoma first came from the Gastrointestinal Tumor
Study Group (GITSG) trial published in 1985, which showed a
significant survival benefit for patients who received 5-fluorouracil
and radiation in spite of a very small sample size owing to
poor accrual.1 A confirmatory study by GITSG confirmed this
earlier study and concluded that the combined use of RT and
fluorouracil as adjuvant therapy after a curative resection is
preferred to no adjuvant therapy.16 However, another random-
ized controlled trial, the European Organisation for Research
and Treatment of Cancer (EORTC) trial 40891, showed no
Table 1 Continued
No RT (N = 5039)
N (%)
Pre-operative
RT (N = 299)
N (%)
Post-operative
RT (N = 3136)
N (%)
Registry
Connecticut 307 (6.1) 22 (7.4) 180 (5.7)
Metropolitan Detroit 265 (5.3) 55 (18.4) 314 (10.0)
Iowa 177 (3.5) 20 (6.7) 162 (5.2)
Seattle (Puget Sound) 224 (4.4) 11 (3.7) 215 (6.9)
Utah 157 (3.1) 17 (5.7) 71 (2.3)
Metropolitan Atlanta 188 (3.7) 11 (3.7) 119 (3.8)
Los Angeles 662 (13.1) 16 (5.4) 215 (6.9)
Greater California 1228 (24.4) 44 (14.7) 630 (20.1)
Kentucky 312 (6.2) 14 (4.7) 220 (7.0)
Louisiana 287 (5.7) 27 (9.0) 217 (6.9)
New Jersey 806 (16.0) 42 (14.0) 557 (17.8)
Greater Georgia 426 (8.5) 20 (6.7) 236 (7.5)
Characteristics of patients undergoing surgery without radiation therapy (RT), pre-operative RT and post-operative RT 2000–2010 (N = 8474).
Figure 1 Trends in the use of radiation therapy for resectable
pancreatic adenocarcinoma from 2000 to 2010
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significant survival benefit for patients treated with chemoradi-
ation versus no chemoradiation. On further subgroup analysis,
the EORTC 40891 trial demonstrated only a trend towards a
significant improvement in survival in those patients with
tumours in the head of the pancreas.7 It is worth noting,
however, that approximately 20% of patients assigned to
chemo-radiotherapy did not receive the assigned treatment.
A population-based study using SEER published in 2008
demonstrated a survival benefit for the use of post-operative
radiation therapy.4 Our study confirmed the survival benefit
associated with post-operative RT in the SEER registry. Two
large single institutional studies also reported a survival benefit
for those patients who received adjuvant chemoradiation ver-
sus no chemoradiation therapy.2,3 However, the study by Cor-
sini et al.3 showed the survival benefit for chemoradiation was
no longer significant for patients with both negative lymph
nodes and low-grade tumours.
Another randomized controlled trial, the Radiation Therapy
Oncology Group (RTOG) 9704 study, evaluated the survival
benefit of gemcitabine versus fluorouracil before and after
chemoradiation. This study found that the addition of gemcit-
abine was associated with a non-statistically significant
improved survival rate but a marked increase in grade 4 hema-
tologic toxicity.5 A subsequent analysis performed by Abrams
et al.6 found that survival was significantly improved for those
patients who received appropriate radiation as outlined by the
trial protocol compared with patients who received radiation
that did not meet the protocol guidelines; these findings sug-
gest that appropriately administered post-operative RT may
positively impact survival.
The results of the ESPAC-1 trial, first published in 2001,
suggested that post-operative chemoradiation may have a dele-
terious effect on survival.8 This study has been critiqued for a
number of reasons including adherence to protocols on deliv-
ery of the RT and the crossover rates between treatment arms.
However, its publication questioned the benefits of post-opera-
Table 2 Predictors of receipt of pre-operative radiation therapy
Predictor OR (95% CI)
Diagnosis year group
2000–2004 1.00 Referent
2005–2010 1.78 (1.360–2.331)
Age categories
18–39 0.38 (0.090–1.567)
40–64 1.86 (1.453–2.384)
65+ 1.00 Referent
Gender
Male 1.00 Referent
Female 0.92 (0.720–1.169)
Race
Non-Hispanic white 1.00 Referent
Black 0.97 (0.661–1.411)
Other 1.11 (0.597–2.051)
Tumour size
<2 cm 1.00 Referent
≥2 cm 1.61 (1.011–2.573)
Missing 1.47 (0.749–2.913)
Tumour grade
1 or 2 1.00 Referent
3 1.001 (0.750–1.336)
4 1.05 (0.323–3.404)
Missing/unknown 2.62 (1.892–3.622)
T-stage
1 and 2 1.00 Referent
3 1.817 (1.305–2.531)
4 8.60 (5.629–13.142)
Surgery type
Whipple 1.00 Referent
Total pancreatectomy 1.02 (0.706–1.462)
Other 0.55 (0.377–0.799)
Node positive
Yes 1.00 Referent
No 0.348 (0.27–0.46)
Nodes examined
0 1.00 Referent
1–9 1.06 (0.649–1.748)
10–14 1.17 (0.689–1.975)
15+ 0.75 (0.436–1.286)
Unknown 0.83 (0.336–2.063)
Registry
Greater California 1.00 Referent
Utah 4.06 (2.234–7.370)
Metropolitan Detroit 3.82 (2.474–5.893)
Table 2 Continued
Predictor OR (95% CI)
Louisiana 2.33 (1.397–3.899)
Iowa 2.20 (1.244–3.873)
Connecticut 2.11 (1.226–3.631)
Metropolitan Atlanta 1.46 (0.717–2.963)
Greater Georgia 1.30 (0.745–2.269)
New Jersey 1.28 (0.822–1.993)
Seattle (Puget Sound) 1.07 (0.541–2.125)
Kentucky 0.98 (0.517–1.844)
Los Angeles 0.77 (0.425–1.382)
Cox’s proportional hazard predictors of receiving pre-operative radia-
tion therapy. Statistically significant predictors of pre-operative radia-
tion therapy are in bold.
OR, odds ratio; CI, confidence interval.
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tive chemoradiation and may have influenced the treatment
patterns for pancreatic adenocarcinoma in the United States.
In a previous study using SEER, Shinohara et al. evaluated the
use of post-operative RT 5 years before and 5 years after the
initial publication of the ESPAC-1 trial in 200117,18 and found
that the use of post-operative RT significantly decreased
between 2001 and 2007. We demonstrate that the use of post-
operative RT continued its decline first observed in 2001
through at least 2010.
While questions about the survival benefit of post-operative
RT remain, a strategy of pre-operative adjuvant therapy offers
a number of potential benefits for patients with adenocarci-
noma of the pancreas.10–14 First, a large proportion of
patients do not receive recommended adjuvant therapy after
surgery secondary to surgical complications.2,3,7 A strategy
utilizing pre-operative adjuvant therapy assures multimodality
treatment to a higher proportion of patients and may
improve survival. Second, delivering pre-operative therapy
allows time for subclinical metastatic disease to become
apparent, thus sparing patients an unnecessary operation if
radiographic metastases are identified before surgery.19 Third,
pre-operative therapy has been associated with a lower likeli-
hood of positive surgical margins and a lower risk of lymph
node metastases.20
The present study found a significant survival benefit for
both pre- and post-operative RT when compared with those
patients receiving surgery alone. This is consistent with two
previous SEER studies that also showed survival benefits for
the use of RT when used in both the pre- and post-operative
setting.4,14 However, conflicting evidence about the survival
benefits of post-operative RT remain and studies evaluating
the survival benefits of pre-operative RT are largely observa-
tional. In addition, the results of randomized trials comparing
pre- versus post-operative adjuvant therapy have not yet been
published. However, in a recently published single-centre study
of patients 70 years of age or greater, Cooper et al. reported
that among patients treated with curative intent, the median
overall survival of all patients who received chemoradiation
therapy first (regardless of whether they underwent surgery)
was similar to that of patients who underwent a resection first.
On further analysis, this study did show that the median
survival of patients who received pre-operative chemoradiation
followed by surgery was 33.8 months as compared with
15.1 months for those treated with surgery first (P = 0.001).21
This study is part of the growing literature that supports the
use of a strategy that includes pre-operative adjuvant therapy.
In our study, we found a modest but significant increase in
the use of pre-operative radiation therapy. To our knowledge,
it is the first study to evaluate trends over time in the use of
pre-operative radiation therapy. The use of pre-operative RT
remains low (3.9%) overall, in spite of the statistically signifi-
cant increase in use over the last 10 years. Our findings are
similar to those reported by Colbert et al. who found that only
5% of their cohort of patients in the National Cancer Database
(NCDB) received pre-operative radiation therapy.20 These find-
ings suggest that the overall use of pre-operative RT may be
Number at risk by 
treatment type 0 months 30 months 5 years (60 months)
Surgery, No RT 5039 1973 1665
Pre-operative RT 299 145 113
Post-operative RT 3136 1304 998
1.0
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Figure 2 Kaplan–Meier curves for overall survival based on the three treatment groups: surgery without radiation therapy (RT),
pre-operative RT then surgery and surgery followed by post-operative RT
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underutilized given the potential benefits of pre-operative adju-
vant therapy that were discussed previously. Furthermore, we
have shown in our study that the survival benefits for patients
who received pre-operative RT are similar to those who
received post-operative therapy, but improved as compared
with those who received surgery alone. When taking these
factors into account, one might expect a greater utilization of
pre-operative adjuvant therapies including radiation therapy.
However, the rates of pre-operative radiation therapy, while
significantly increasing over this study period, still remain low.
Additionally, our study evaluated other factors associated
with survival. Consistent with other population-based studies,
we found that an increased risk of death was associated with
larger tumour size, higher tumour grade and lymph node posi-
tivity.4,20 Of note, a more recent year of diagnosis was associ-
ated with a decreased hazard of death. This finding is in
contrast to a recently published large single-institutional study
by Winter et al.22 that demonstrated no improvement in long-
term survival based on a decade of diagnosis. In fact, they note
that the long-term survival of those patients who survived
1 year after surgery was significantly worse in the 2000s as
compared to the 1990s.
Finally, this study also evaluated factors that influence the
use of pre-operative radiation therapy. On multivariate analysis
comparing those patients that received pre-operative RT with
patients that received either surgery alone or surgery plus post-
operative radiation therapy, we found that pre-operative RT
was significantly associated with younger age, recent year of
treatment, advanced T stage and type of surgical treatment. In
the NCDB study, a univariate analysis was used to compare
the group that received pre-operative RT with the group that
received post-operative radiation therapy; this analysis found
that lower T stage, higher use of chemotherapy and treatment
Table 3 Cox proportional hazard model: 5-year relative hazard of
death
Hazard ratio 95% CI P value
Treatment group
No RT 1.00 Referent
Pre-operative RT 0.64 0.55–0.74 <0.0001
Post-operative RT 0.69 0.65–0.73 <0.0001
Year
2000–2004 1.00 Referent
2005–2010 0.85 0.81–0.90 <0.0001
Age
18–39 1.00 Referent
40–64 0.41 0.32–0.53 <0.0001
65+ 0.81 0.77–0.85 <0.0001
Gender
Male 1.00 Referent
Female 0.90 0.86–0.95 0.0001
Race
Non-Hispanic white 1.00 Referent
Black 1.14 1.05–1.25 0.002
Other or unknown 0.96 0.84–1.09 0.521
Tumour size
<2 cm 1.00 Referent
≥2 cm 1.39 1.27–1.52 <0.0001
Missing 1.37 1.19–1.59 <0.0001
Tumour grade
1 or 2 1.00 Referent
3 1.39 1.31–1.47 <0.0001
4 1.78 1.42–2.23 <0.0001
Missing/unknown 0.83 0.75–0.93 0.0009
T-stage
1 and 2 1.00 Referent
3 1.39 1.30–1.49 <0.0001
4 2.03 1.79–2.30 <0.0001
Surgery type
Whipple 1.00 Referent
Total pancreatectomy 1.12 1.03–1.22 0.007
Other 0.95 0.89–1.03 0.240
Node positive
No 1.00 Referent
Yes 1.57 1.48–1.66 <0.0001
Nodes examined
1–14 1.00 Referent
15+ 0.84 0.80–0.89 <0.0001
Table 3 Continued
Hazard ratio 95% CI P value
Registry
Connecticut 1.00 Referent
Kentucky 1.33 1.19 1.49 <0.0001
Greater Georgia 1.22 1.09 1.36 0.0002
Louisiana 1.18 1.05 1.33 0.006
Iowa 1.15 1.03 1.29 0.013
Los Angeles 1.09 0.94 1.26 0.271
Metropolitan Atlanta 1.04 0.89 1.23 0.610
New Jersey 0.98 0.90 1.07 0.801
Seattle (Puget Sound) 0.93 0.80 1.07 0.271
Greater California 0.88 0.80 0.97 0.009
Utah 0.86 0.75 0.97 0.021
Metropolitan Detroit 0.82 0.72 0.93 0.002
Association between pre-operative radiation therapy (RT) and 5-year
relative hazard of death. Statistically significant predictors of relative
hazard of death are in bold
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at an academic/research facility were significantly associated
with pre-operative radiation therapy.20 The association between
pre-operative RT use and advanced T-stage in our study may
be related to the increased use of pre-operative RT to poten-
tially downstage larger and borderline-resectable tumours.
Our study has several SEER-related limitations. First, we
cannot assess the role of misdiagnosis or whether the patient
was diagnosed based on symptoms or on routine screening or
imaging. Detailed patient and tumour information that may
have influenced treatment decisions were not available from
the cancer registry database. For example, we were unable to
adjust for co-morbidities because these data are not collected
by SEER. In addition, the impact, of treating facility volume
and/or teaching status, could not be assessed with this data
set. We were also unable to determine certain factors that
may have influenced the use of adjuvant RT from the SEER
database. For example, the presence of positive margins and
the occurrence of post-operative complications may have
impacted treatment decisions but were unable to be assessed.
Also, we were unable to assess the impact of chemotherapy
use because SEER does not collect these data. However, a
number of other studies have shown that when RT is used,
chemotherapy is almost uniformly used for the treatment of
pancreatic adenocarcinoma.3,20 Thus, while the data on
chemotherapy use are not known for this cohort, the vast
majority of those receiving RT were likely receiving
chemotherapy as well. Another limitation of this study is
the relatively small sample size of the pre-operative RT group
(n = 299) compared with the post-operative RT and no RT
groups. In addition, the overall quality of radiotherapy admin-
istered cannot be analysed. In spite of these limitations, the
findings of our study provide important information about
the use of pre-operative RT in the United States.
In conclusion, we found that administration of pre-operative
RT significantly increased during the study period, but use
remains low overall. We also noted significant variability in the
use of pre-operative RT based on geographic regions. Thus, the
overall use of pre-operative RT is likely underutilized, given the
potential benefits of a pre-operative treatment strategy. How-
ever, this local variability offers a natural experiment to better
understand the impact of the RT strategy on survival after pan-
creatic cancer diagnosis. Given the poor overall survival for per-
sons diagnosed with pancreatic adenocarcinoma and the
persistent questions on the timing and benefit of adjuvant ther-
apy, further prospective randomized controlled trials are needed;
we recommend randomized controlled trials specifically
comparing pre- versus post-operative adjuvant therapies includ-
ing radiation, chemotherapy and combined chemoradiation.
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